NPR logo

Heparin Hearing on Capitol Hill Turns Feisty

  • Download
  • <iframe src="https://www.npr.org/player/embed/89850138/89850099" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript
Heparin Hearing on Capitol Hill Turns Feisty

Health Care

Heparin Hearing on Capitol Hill Turns Feisty

Heparin Hearing on Capitol Hill Turns Feisty

  • Download
  • <iframe src="https://www.npr.org/player/embed/89850138/89850099" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

The head of the Food and Drug Administration Andrew von Eschenbach testifies before a House subcommittee about planned improvements to oversee the foreign manufacture of drug ingredients. The hearing comes after tainted batches of the blood thinner Heparin were linked to a dozen Chinese companies.

Marcia Crosse, a health care director for the Government Accountability Office who testified at the hearing, talks with Melissa Block about how much it would cost to inspect foreign drug plants.

We no longer support commenting on NPR.org stories, but you can find us every day on Facebook, Twitter, email, and many other platforms. Learn more or contact us.